A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to '18 Years With Chronic Kidney Disease on Dialysis
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Lanthanum carbonate (Primary) ; Calcium carbonate
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Shire
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Planned number of patients changed from 50 to 65.
- 25 Jan 2017 Planned End Date changed from 1 Jun 2017 to 9 Jul 2018.